Table 2.
Projected revenue from sales of pembrolizumab comparing scenarios with revenue only from administered drug, revenue based on 50 mg vial sizes with reimbursement for leftover drug, and revenue based on 100 mg vial sizes with reimbursement for leftover drug. Data based on pooled analyst estimates compiled by Defined Health.
| Year of sales | Revenue from dose only ($m) | Revenue from dose and leftover using 50 mg vials ($m) | Revenue from dose and leftover using 100 mg vials ($m) |
|---|---|---|---|
| 2016 | 762 | 862 | 964 |
| 2017 | 1335 | 1510 | 1690 |
| 2018 | 1991 | 2253 | 2520 |
| 2019 | 2346 | 2654 | 2969 |
| 2020 | 2687 | 3040 | 3401 |
| Total | 9121 | 10 320 | 11 544 |